Step-by-Step Guide to Designing In-Process Sampling Plans for Tablets and Capsules

In pharmaceutical manufacturing, controlling product quality throughout the production process is paramount to ensure safety, efficacy, and regulatory compliance. In process controls in pharmaceutical manufacturing serve as pivotal checkpoints that monitor critical parameters to detect deviations early and maintain consistent product standards. For solid oral dosage forms like tablets and capsules, well-designed sampling plans form the backbone of effective in-process controls (IPCs), facilitating timely decisions on batch disposition and preventing costly recalls.

This tutorial provides a comprehensive, stepwise methodology to design robust in-process sampling plans tailored for tablets and capsules. The approach aligns with FDA 21 CFR Parts 210/211, EU GMP Annex 15, PIC/S guidelines, and ICH Q7 and Q10 principles, assuring conformance with global regulatory expectations. Emphasis is placed on the scientific rationale for sampling, techniques for blend sampling, and vigilance through compression checks during tableting processes.

Step 1: Understand the Role and Regulatory Expectations of In-Process Controls

The foundation for any in process controls in pharmaceutical manufacturing is a thorough comprehension of their purpose and regulatory framework. IPCs are embedded checks performed during manufacturing that evaluate critical quality attributes (CQAs) and critical process parameters (CPPs) at various stages, enabling real-time or near-real-time quality assurance.

For tablets and capsules, the FDA’s 21 CFR Part 211 details specific mandates related to sampling frequency, sample size, testing methods, and documentation. Similarly, the EU GMP Annex 15 outlines expectations for process validation and in-process testing, highlighting that IPCs must be scientifically justified and statistically sound.

To start, manufacturers should identify the process stages relevant for sampling:

• Powder or granule blending
• Pre-compression blend uniformity
• Compression (tablet press) checks
• Encapsulation process consistency
• Post-compression moisture content and hardness (optional but beneficial)

At each step, the goal of IPCs is to detect deviations from established quality limits promptly, enabling correction before the process continues or final product release.

Step 2: Define Critical Quality Attributes and Sampling Rationales

Establishing a sound in-process sampling plan begins with identifying the Critical Quality Attributes (CQAs) associated with tablets and capsules. CQAs often include:

• Blend uniformity
• Assay content per dosage unit
• Weight variation
• Hardness and friability
• Disintegration and dissolution profiles
• Moisture content

Not all CQAs require in-process sampling at every stage; select those where variability can lead to product failure or regulatory non-compliance. For instance, blend uniformity is critical at the mixing stage and before compression, as inadequate mixing can cause dose variation.

The rationale for sampling at each stage should be based on process risk assessments such as ICH Q9 Quality Risk Management principles. For example, the risk of segregation during transfer of blended powder would justify extensive blend sampling, while compression checks monitor machine performance to ensure uniform dosage form production.

Sample collection points must represent the entire batch. For blending, sampling at multiple points and depths prevents localized misrepresentation. Similarly, compression checks should cover changes over time due to machine drift or component variability.

Step 3: Determine Sampling Frequency and Sample Size Using Statistical Considerations

Once CQAs and sampling rationales are defined, the next step involves determining appropriate sampling frequency and sample size. These parameters are critical for the reliability of in-process sampling plans and must balance regulatory requirements with operational feasibility.

Statistical tools guide this determination:

• Sampling frequency: relates to the production batch size and process dynamics. For tablet compression, it might involve sampling every set number of tablets (e.g., every 30 minutes or every 10,000 tablets).
• Sample size: determines the number of units or portions per sampling event to be tested. For blend uniformity, often 10 to 30 samples taken at random locations are analyzed to assess homogeneity.

ICH Q7 and FDA guidance documents emphasize that sampling must be representative and sufficiently frequent to quickly detect out-of-trend results. Acceptable sampling plans use recognized statistical standards such as the minimum number of units per batch to set confidence intervals. For complex blend systems, stratified sampling could be implemented to address powder segregation risks effectively.

For example, during blend sampling:

• Collect at least 10 samples uniformly throughout the batch volume.
• Samples must come from different locations vertically and horizontally in the blender.
• Perform blend uniformity testing using validated analytical methods such as high-performance liquid chromatography (HPLC).

Compression checks typically consist of:

• Visual inspection of tablets for defects
• Weight variation tests on a defined number of tablets (e.g., 30 tablets per shift)
• Hardness and thickness measurement or pressure reading from the compression machine

Step 4: Implement Sampling Techniques for Blend Sampling and Compression Checks

Effective sampling requires validated methods that minimize contamination risks and optimize representativeness. For tablets and capsules, two critical IPC techniques are blend sampling and compression checks.

4.1 Blend Sampling Methodologies

Proper sampling from a powder blend requires systematic approaches:

• At-point sampling: Powder is sampled from defined points during blending; often, standard guidelines advocate for samples from at least 10 locations.
• Grab sampling: Using a spatula or sampling thief, samples are extracted from the blender’s bulk but risk non-representativeness if not performed correctly.
• Composite sampling: Multiple samples combined proportionally to form one composite sample analyzed for uniformity.

Ensure sampling devices and containers are clean, inert, and comply with GMP to avoid cross-contamination. All tools shall be validated and periodically inspected.

4.2 Compression Checks During Tablet Manufacture

Compression stage sampling involves continuous or interval checks to assess machine and tablet performance:

• Obtain random samples of tablets at defined intervals to evaluate weight variation and surface defects.
• Check tablet hardness and thickness with calibrated instruments.
• Monitor the compression force and turret speed parameters on the press.

If deviations are observed, immediate investigation and corrective action must be taken prior to continued production. Records must capture all sampling results, environmental conditions, and operator details per GMP requirements.

Step 5: Document Sampling Procedures and Integrate into Quality Systems

All designed sampling plans must be precisely documented in procedural documents such as SOPs and batch manufacturing records to ensure consistent execution. Key elements to be included:

• Sampling locations and intervals
• Sample size and method of collection
• Acceptance criteria for in-process tests
• Actions to be taken in case of out-of-specification (OOS) results
• Training requirements for personnel performing sampling
• Links to analytical methods and instrument calibration

Integration with the broader pharmaceutical quality system is essential. This includes:

• Linking IPC data to process validation documentation and ongoing process verification per ICH Q10.
• Incorporating sampling results in batch records and quality review documentation.
• Facilitating trending analysis to detect process drifts or deviations early.

Electronic batch records or Manufacturing Execution Systems (MES) can improve traceability and real-time review of in-process testing data.

Step 6: Conduct Regular Review, Training, and Continuous Improvement of Sampling Plans

Sampling plans are living documents that require periodic review and adjustment based on:

• Process changes or scale-up activities
• Empirical data and trending results indicating process drift or recurring deviations
• Regulatory audit findings or inspection observations
• Implementation of new technologies or equipment

Personnel involved in sampling must be trained on the rationale, methods, and documentation requirements to maintain GMP compliance. Refresher training should be scheduled based on quality system policies.

Assessment of the statistical appropriateness of sampling frequency and sample size should be revisited regularly, leveraging quality metrics and risk-based approaches in alignment with WHO GMP guidelines.

Continuous improvement activities may include:

• Optimization of sampling techniques to reduce waste and contamination risk
• Incorporation of Process Analytical Technology (PAT) tools to supplement or partially replace manual sampling
• Enhanced data analytics for predictive process control

Conclusion

Designing a GMP-compliant, scientifically justified in-process sampling plan for tablets and capsules is a multidimensional task that requires a systematic, stepwise approach. By understanding regulatory expectations, defining CQAs and sampling rationales, applying sound statistical methodologies, implementing validated sampling techniques, and integrating documentation within quality systems, pharmaceutical manufacturers can ensure robust and reliable in process controls in pharmaceutical manufacturing.

Ongoing review and training are critical to sustain sampling proficiency and adapt to evolving processes. Establishing such comprehensive sampling plans not only satisfies regulators like the FDA, EMA, and MHRA but also significantly reduces batch failures, protects patient safety, and maintains product quality consistency.